angiotensin-converting enzyme 2

angiotensin-converting enzyme 2
Name	Angiotensin-converting enzyme 2
Uniprot	Q9BYF1
Organism	Human

angiotensin-converting enzyme 2 is a zinc metallopeptidase and type I membrane protein first characterized in the early 2000s associated with the renin–angiotensin system and viral entry. Discovered during molecular cloning efforts, it rapidly became central to research in cardiovascular biology, pulmonary medicine, virology, and pharmacology due to links with heart failure, acute respiratory distress, and coronavirus infection. The protein is widely studied across basic science and clinical domains by groups at institutions such as Harvard University, Johns Hopkins University, University of Oxford, National Institutes of Health, and Centers for Disease Control and Prevention.

Structure and function

ACE2 is a single-pass membrane protein with an N-terminal peptidase domain that contains a zinc-binding motif structurally related to metalloproteases like angiotensin-converting enzyme and Neprilysin. High-resolution structures obtained by teams at Stanford University and University of Texas using X-ray crystallography and cryo-electron microscopy revealed an extracellular catalytic domain, a collectrin-like dimerization region, and a short cytosolic tail implicated in trafficking similar to motifs characterized at Massachusetts Institute of Technology. The catalytic mechanism uses a HEXXH zinc-binding signature shared with enzymes studied at Max Planck Society laboratories and modeled in structural biology work connected to European Molecular Biology Laboratory. ACE2 enzymatic activity converts angiotensin I to angiotensin-(1–9) and cleaves angiotensin II to angiotensin-(1–7), thereby counterbalancing reactions catalyzed by angiotensin-converting enzyme described in foundational studies from Karolinska Institute and Imperial College London.

Expression and regulation

ACE2 expression is tissue-specific, with high levels in lung alveolar epithelium, small intestine, vascular endothelium, heart myocardium, and kidney proximal tubules, mapped in atlases produced by Human Protein Atlas and consortiums like the ENCODE Project. Regulation occurs at transcriptional and post-translational levels via factors including hypoxia-inducible factor 1-alpha interactions investigated at University of Cambridge, epigenetic mechanisms examined at Broad Institute, and proteolytic shedding mediated by metalloproteases such as ADAM17 studied at University of California, San Francisco. Hormonal modulation from aldosterone and estrogen pathways, as well as interferon-stimulated signaling characterized by groups at Pasteur Institute, influence ACE2 abundance during developmental stages researched at Johns Hopkins University School of Medicine.

Physiological roles and pathways

ACE2 is integral to the renin–angiotensin system axis, generating angiotensin-(1–7) ligands that activate the Mas receptor and downstream signaling cascades investigated in cardiovascular centers at Cleveland Clinic and Mayo Clinic. By degrading angiotensin II, ACE2 reduces vasoconstriction, sodium retention, and profibrotic signaling implicated in models developed at Salk Institute and Weizmann Institute of Science. Cross-talk with bradykinin pathways and nitric oxide signaling has been observed in vascular research from Columbia University and UCLA. ACE2 also participates in amino acid transport regulation through its collectrin-like domain, linking it to intestinal nutrient absorption and microbiome interactions studied at Wageningen University and University of Copenhagen.

Clinical significance and disease associations

Altered ACE2 expression or activity has been associated with hypertension cohorts analyzed at Johns Hopkins Hospital, heart failure registries at Cleveland Clinic Foundation, and chronic kidney disease populations treated at Mayo Clinic Hospital. Reduced ACE2 is implicated in pulmonary diseases including acute respiratory distress syndrome case series reported at Massachusetts General Hospital and chronic obstructive pulmonary disease cohorts from Karolinska University Hospital. Genetic studies and genome-wide association consortia such as those at University of Oxford and Wellcome Trust Sanger Institute have linked ACE2 locus variation to cardiovascular phenotypes and metabolic traits evaluated in large biobanks including UK Biobank. ACE2 dysregulation interacts with inflammatory pathways studied by investigators at National Institute of Allergy and Infectious Diseases and World Health Organization surveillance programs.

Interaction with pathogens and role in infection

ACE2 serves as a functional receptor for several coronaviruses, notably those characterized in outbreaks studied by Wuhan Institute of Virology, Centers for Disease Control and Prevention, and international collaborations tracing SARS-CoV and SARS-CoV-2 emergence. Structural studies from University of Cambridge and Ragon Institute mapped spike protein binding to the ACE2 peptidase domain, clarifying tropism for respiratory epithelium and explaining clinical patterns observed in pandemic reports coordinated by World Health Organization and European Centre for Disease Prevention and Control. Viral engagement can downregulate surface ACE2 via internalization and shedding processes linked to ADAM17 activity, exacerbating angiotensin II–mediated injury in models developed at Fred Hutchinson Cancer Research Center and Institut Pasteur. Experimental infections in animal models maintained at Rockefeller University and National Institutes of Health facilities have been used to probe ACE2-dependent pathogenesis and transmission dynamics analyzed by groups such as Imperial College London.

Therapeutic targeting and pharmacology

ACE2 is a therapeutic target for cardiovascular and infectious disease interventions, from recombinant soluble ACE2 biologics trialed in clinical studies run by institutions like Mount Sinai Hospital and Mayo Clinic to small-molecule modulators pursued by pharmaceutical companies headquartered in Basel and Cambridge, Massachusetts. Drugs that influence the renin–angiotensin system—including angiotensin receptor blockers and ACE inhibitors evaluated in landmark trials at Framingham Heart Study centers—affect ACE2-related pathways and clinical outcomes assessed by National Heart, Lung, and Blood Institute. Monoclonal antibodies, decoy receptors, and vaccine strategies against ACE2-binding pathogens have been developed by consortia including GAVI and industry partners such as Pfizer and Moderna. Safety, efficacy, and pharmacokinetics have been reported in multicenter trials coordinated with regulatory agencies like Food and Drug Administration and European Medicines Agency.

Category:Human proteins